Dishman Pharmaceuticals and Chemicals has suffered a setback during the year ended March 2012 and its consolidated net profit declined by 29 per cent to Rs.56.80 crore from Rs.80.01 crore in the previous year. Its consolidated net sales improved to Rs.1,122 crore from Rs.991 crore, a growth of 13.2 per cent. Its EBDITA moved up by 9.6 per cent to Rs.237.48 crore from Rs.216.75 crore. With lower net profit, its earnings per share declined to Rs.7.03 from Rs.9.92 in the last year. Its interest cost went up by 30.5 per cent to Rs.72.94 crore from Rs.55.88 crore.

The company's sales from CRAMS improved by 9.4 per cent to Rs.716.45 crore from Rs.654.72 crore and that from other business improved by 20.7 per cent to Rs.405.60 crore from Rs.336.12 crore. The profits from CRAMS declined by 20.7 per cent to Rs.94.37 crore from Rs.119.06 crore and the same from other business increased by 129 per cent to Rs.66.58 crore from Rs.28.97 crore.

On standalone basis, Dishman's net sales improved by 10.1 per cent to Rs.462 crore from Rs.419.57 crore and its net profit improved to Rs.44.84 crore from Rs.40.12 crore in the previous year.